CHOP Regimen for Intermediate Grade Non-Hodgkins Lymphoma at Maharat Nakhon Ratchasima Hospital: Efficacy and Preliminary Outcomes
Main Article Content
Abstract
Abstract: The non-Hodgkins lymphomas (NHL) are a diverse group of diseases that differ with regard to histologic appearance, age of incidence, sites of involvement, clinical course and response to therapy. The objective of this study was to evaluate the efficacy of the CHOP regimen. The eligibility criteria included (1) patients between the ages of 15 and 60 years (2) biopsy-proven NHL, of intermediate grade (3) stage II, III, or IV (4) no prior therapy (5) absence of clinically apparent CNS disease (6) clinically adequate heart and lung function, and adequate kidney function. Treatment consisted of cyclophosphamide 750 mg/m2, doxorubicin 45 mg/m2 and vincristine 1.4 mg/m2 IV on day 1. Prednisolone 60 mg/m2 orally was administered on day 1 to 7. Courses were repeated every 28 days and evaluation was done after 6 courses of chemotherapy. The results of treatment indicated that CHOP regimen was active with 80% complete remission. The median time to complete remission was 2 months. One-year survival rate was 96.7%. CHOP regimen can be administered safely and the complete response rate support the previous studies using CHOP as the standard treatment.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Foon KA, Fisher RI. Lymphomas. In: Ernest B, Marshall A, eds. Williams Hematology. 5th ed. New York: McGraw-Hill; 1995:1076-96.
Lekhakula A, Thamprasit T. Malignant lymphor Songklanagarind Hospital; a retrospective analysis of 300 cases. เสนอในการประชุมวิชาการประจำปี ครั้งที่ 5 ของราชวิทยาลัยอายุรแพทย์แห่งประเทศไทย 2532.
วิชัย ประยูรวิวัฒน์, ถนอมศรี ศรีชัยกุล. Clinicopathological analysis of malignant lymphoma; report of 101 cases from Pramongkutklao Hospital 1982-1985. Intern Med 1986;2:193-200.
Simon R, Durrleman S, Hoppe RT, et al. The Non-Hodgkin Lymphoma pathological classification project: long-term follow up of 1,153 patients with Non- Hodgkin Lymphomas. Ann Intern Med 1988;109:939-45.
Lieberman PH, Filippa DA, Straus DJ, et al. Evaluation of malignant lymphoma: using three classifications and working formulation. Am J Med 1981;3:365-80.
The non-Hodgkins lymphoma Pathologic Classification Project Writing Committee: National Cancer Institute sponsored study of classification of non-Hodgkins lymphoma. Cancer 1982;49:2112-35.
Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkins disease staging classification. Cancer Res 1971;31:1860-1.
Miller AB, Hocgstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
McKelvey EM, GoHlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant Iymphoma. Cancer 1976:38:1484-93.
Fisher RI, Miller TP, Dona BW, et al. Southwest oncology group clinical trials for intermediate and high grade non-Hodgkins lymphomas. Semin Hematol 1988;25:17-22.
Armitage JO, Fufe MAE, Leuris J. Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with CHOP regimen. J Clin Oncol 1984;2:898.
Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 1985;102:596-602.
Fisher RI, Devita VT, Hubbard SM, et al. Randomized trial of ProMACE-MOPP vs. ProMACE-CytoBOM in previously untreated advanced stage, diffuse aggressive lymphomas [abstract). Proc Am Soc Clin Oncol 1984;3:242.
Jones SE, GroZea PN, Metz EN, et al. Superiority of adriamycin containing combination chemotherapy in treatment of diffuse lymphoma. Cancer 1979;43:417-25.
Peter IY, Morton C, Leonard S, et al. Chemotherapy of large cell lymphoma: a status update. Semin Oncol 1990;17:60-73.
แสงสุรีย์ จูหา, สาวิตรี เมาฟิโรจนกุล, วิชัย อติชาตการ. A ma- lignant lymphoma in Ramathibodi Hospital uaualunns ประชุมใหญ่ทางวิชาการประจำปีของสมาคมโลหิตวิทยาแห่งประเทศไทย 2529.
Dixon DO, Neilan B, Jones JE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma. J Clin Oncol 1986;4:295.
Coleman M, Gerstein G, Topilow A, et al. Advances in chemotherapy for large cell lymphoma. Semin Hematol 1987;24:8-20.